Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2Phase 1/2 2Phase 4 1Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

NET 2Endocrine 2Thoracic 1Sarcoma 1Head & Neck 1Gastrointestinal 1

Conditions

Small Cell Lung Carcinoma 3Sarcoma 3Pancreatic Neoplasms 2Osteosarcoma 2Neuroendocrine Tumors 2Triple Negative Breast Neoplasms 1Thyroid Carcinoma, Anaplastic 1Stomach Neoplasms 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Ovarian Neoplasms 1Neuroectodermal Tumors, Primitive 1Neoplasms 1Neoplasm Metastasis 1Lymphoma 1Colorectal Neoplasms 1Carcinoma, Neuroendocrine 1Carcinoid Tumor 1Biliary Tract Neoplasms 1Advanced Colorectal Cancer 1

Interventions

lutetium Lu 177 dotatate 5gallium Ga 68 dotatate 3surufatinib 2olaparib 2atezolizumab 2Everolimus 23-Iodobenzylguanidine 2tivozanib 1tislelizumab 1repotrectinib 1pralsetinib 1pembrolizumab 1lanreotide 1cabozantinib 1avelumab 1arginyllysine 1amino-acid, glucose, and electrolyte solution 1Tirapazamine 1Temozolomide 1TKM-080301 1S 1 (combination) 1Radiotherapy 1Positron-Emission Tomography 1Positron Emission Tomography Computed Tomography 1PT-100 dipeptide 1PM 01183 1Ondansetron 1Magnetic Resonance Spectroscopy 1Lutetium-177 1Irinotecan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Neuroendocrine Tumors × surufatinib × Clear all
NCT05077384 2025-09-16

Open-label Study of Surufatinib in Japanese Patients

Hutchmed

Phase 1/2 Completed
36 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT04579757 2025-05-08

Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors

Hutchmed

Phase 1/2 Terminated
87 enrolled 29 charts
EndocrineGastrointestinalHead & NeckNETSarcomaThoracic

Neoplasm Metastasis, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Neuroendocrine Tumors, Small Cell Lung Carcinoma, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡